Other Events. On August 25, 2026, the Company announced topline results from the RA sub-study of the Phase 2 SKYWAY basket trial evaluating SPY072 in rheumatic diseases. SPY072 SKYWAY-RA Sub-Study Topline Results The SKYWAY-RA sub-study is one of three sub-studies in the SKYWAY basket trial and is a randomized and placebo-controlled study evaluating two doses of SPY072 in patients with moderate to severely active RA with inadequate response to conventional or advanced therapies. The primary e…

Results of Operations and Financial Condition. On August 4, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw…

The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.

Results of Operations and Financial Condition. On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Entry into a Material Definitive Agreement On April 14, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 6,500,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”…

Other Events. On April 13, 2026, the Company announced positive initial 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY001 for the treatment of moderate-to-severely active UC. Additionally, the Company announced that recruitment for Part A of the SKYLINE Trial is now closed and enrollment is open for Part B, which includes three monotherapy cohorts (SPY001, SPY002, and SPY003) and three combination cohorts (SPY120, SPY130, and SPY230) into which participants may…

Other Events. Effective April 13, 2026, the Company suspended and terminated the prospectus (the “ATM Prospectus”) relating to the sale of its common stock, $0.0001 par value per share (the “Common Stock”) in an “at-the-market” offering pursuant to the terms of the Sales Agreement, dated, September 6, 2024, by and between the Company and TD Securities (USA) LLC (the “Sales Agreement”). As a result, the Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless…

Results of Operations and Financial Condition. On April 13, 2026, Spyre Therapeutics, Inc. (the “Company”) announced that while the Company has not finalized its full financial results for the quarter ended March 31, 2026, the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026. This amount includes $30 million of legacy asset disposition proceeds collected during the quarter ended March 31, 2026, of which a…

Results of Operations and Financial Condition. On February 19, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Ex…

Results of Operations and Financial Condition. On November 4, 2025, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…

Other Events. On November 4, 2025, the Company announced positive interim Phase 1 results from its first-in-human trial of SPY003, an investigational, extended half-life antibody targeting the p19 subunit of IL-23. Key Phase 1 Interim Findings The SPY003 Phase 1 trial was a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and pharmacokinetic ("PK") in healthy volunteers. The trial enrolled 59 healthy adult participants into five single-ascending d…

Entry into a Material Definitive Agreement On October 13, 2025, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 14,864,865 shares of the Company’s common stock, par value $0.0001 per share (th…

Results of Operations and Financial Condition. On October 14, 2025, Spyre Therapeutics, Inc. (the “Company”) announced that while the Company has not finalized its full financial results for the quarter ended September 30, 2025, the Company expects to report that it had approximately $486.2 million of cash, cash equivalents and marketable securities as of September 30, 2025. This amount is preliminary, has not been audited and is subject to completion of the Company’s financial closing proced…

Results of Operations and Financial Condition. On August 5, 2025, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw…

Other Events. On June 17, 2025, the Company announced positive interim Phase 1 results from its first-in-human trials of SPY002 (formerly SPY002-091) and SPY072 (formerly SPY002-072), two investigational, novel, extended half-life monoclonal antibodies targeting TL1A. In addition, the Company announced the initiation of its SKYLINE-UC platform trial and unveiled its SKYWAY-RD basket trial evaluating anti-TL1A targeted therapy in three rheumatologic indications. Single doses of up to 1500 mg f…

Results of Operations and Financial Condition. On May 8, 2025, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On February 28, 2025, the Audit Committee (the “Audit Committee”) of Board of Directors (the “Board”) of Spyre Therapeutics, Inc. (the “Company”), dismissed PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm, effective immediately. PwC served as the independent registered public accounting firm of the Company since 2014. The reports of Pw…

Results of Operations and Financial Condition. On February 27, 2025, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Ex…

Results of Operations and Financial Condition The information set forth below under “Preliminary Financial Information for the Year Ended December 31, 2024” in

Entry into a Material Definitive Agreement On November 18, 2024, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters named therein (the “Underwriters”), relating to the offer and sale (the “Offering”) of 7,275,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Sto…

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. On November 18, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors of Spyre Therapeutics, Inc. (the “Company”), after consultation with the Company’s management and independent registered public accounting firm, concluded, due to the treatment of preferred stock in the calculation of the Company’s net loss per share, that the Company’s previously issued audite…

Other Events. We operate in a rapidly changing environment that involves a number of risks that could materially affect our business. For a detailed discussion of the risks that affect our business, please refer to Part I - Item 1A, "Risk Factors," in our Quarterly Report on Form 10-Q for the period ended September 30, 2024, which was filed with the SEC on November 7, 2024. There have been no material changes to the risk factors as previously disclosed in our Quarterly Report on Form 10-Q, ex…

Other Events. On November 12, 2024, the Company announced positive interim Phase 1 data from its first-in-human trial of SPY001. SPY001 was well-tolerated. Pharmacokinetic (“PK”) data observations included a half-life of >90 days and pharmacodynamic (“PD”) data observations included complete target engagement at all time points available. The Company believes that that these PK and PD results support potential for optimized Phase 2 dosing including (i) increased induction exposures with the p…

Results of Operations and Financial Condition. On November 7, 2024, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherw…

Entry into a Material Definitive Agreement. IL-23 (SPY003) License Agreement – Paragon Therapeutics, Inc. On October 11, 2024, Spyre Therapeutics, Inc., a Delaware corporation (the “Company”), and Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), entered into a license agreement (the “SPY003 License Agreement”), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibo…